PMID- 29115429
OWN - NLM
STAT- MEDLINE
DCOM- 20180709
LR  - 20211204
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 17
IP  - 1
DP  - 2018 Jan
TI  - Resveratrol-mediated apoptosis in renal cell carcinoma via the p53/AMP‑activated 
      protein kinase/mammalian target of rapamycin autophagy signaling pathway.
PG  - 502-508
LID - 10.3892/mmr.2017.7868 [doi]
AB  - Resveratrol, known as phytoalexin, is a natural compound. Clinical studies have 
      revealed that resveratrol has a variety of effects including anti‑inflammatory, 
      antivirus and tumor suppressor activities. It has been reported that it may serve 
      an important role in renal cell carcinoma (RCC) however, the molecular mechanism 
      underlying resveratrol‑induced apoptosis in RCC is still unclear. The aim of the 
      present study was to determine whether resveratrol could suppress RCC 
      progression. Analysis of apoptosis demonstrated that resveratrol may act as a RCC 
      suppressor in a dose‑ and time‑dependent manner. In addition, the results of the 
      MTT and cell migration experiments revealed that resveratrol significantly 
      decreased cell viability and migration. In addition, the expression of the 
      anti‑apoptosis gene B‑cell lymphoma 2 (Bcl‑2) was downregulated by resveratrol, 
      and the expression of pro‑apoptosis gene Bcl‑2‑associated X was upregulated at 
      the mRNA and protein levels. Resveratrol also promoted the expression of p53 and 
      activated phospho‑AMP‑activated protein kinase (AMPK). The phosphorylation of 
      mammalian target of rapamycin (mTOR) was inhibited and the autophagy‑associated 
      genes, light chain 3, autophagy related (ATG)5 and ATG7, were upregulated at the 
      mRNA and protein levels. In conclusion, resveratrol suppressed RCC viability and 
      migration, and promoted RCC apoptosis via the p53/AMPK/mTOR‑induced autophagy 
      signaling pathway.
FAU - Liu, Qingjun
AU  - Liu Q
AD  - Department of Urology, Beijing Ditan Hospital, Capital Medical Science, Beijing 
      100015, P.R. China.
FAU - Fang, Qiang
AU  - Fang Q
AD  - Department of Urology, First Hospital of Fangshan District, Beijing 102400, P.R. 
      China.
FAU - Ji, Shiqi
AU  - Ji S
AD  - Department of Urology, Beijing Ditan Hospital, Capital Medical Science, Beijing 
      100015, P.R. China.
FAU - Han, Zhixing
AU  - Han Z
AD  - Department of Urology, Beijing Ditan Hospital, Capital Medical Science, Beijing 
      100015, P.R. China.
FAU - Cheng, Wenlong
AU  - Cheng W
AD  - Department of Urology, Beijing Ditan Hospital, Capital Medical Science, Beijing 
      100015, P.R. China.
FAU - Zhang, Haijian
AU  - Zhang H
AD  - Department of Urology, Beijing Ditan Hospital, Capital Medical Science, Beijing 
      100015, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20171025
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Stilbenes)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - AMP-Activated Protein Kinases/*metabolism
MH  - Autophagy/*drug effects
MH  - Carcinoma, Renal Cell/genetics/metabolism/pathology
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Cell Survival/drug effects
MH  - Gene Expression
MH  - Humans
MH  - Resveratrol
MH  - Signal Transduction/*drug effects
MH  - Stilbenes/*pharmacology
MH  - TOR Serine-Threonine Kinases/*metabolism
MH  - Tumor Suppressor Protein p53/genetics/*metabolism
EDAT- 2017/11/09 06:00
MHDA- 2018/07/10 06:00
CRDT- 2017/11/09 06:00
PHST- 2017/05/10 00:00 [received]
PHST- 2017/08/31 00:00 [accepted]
PHST- 2017/11/09 06:00 [pubmed]
PHST- 2018/07/10 06:00 [medline]
PHST- 2017/11/09 06:00 [entrez]
AID - 10.3892/mmr.2017.7868 [doi]
PST - ppublish
SO  - Mol Med Rep. 2018 Jan;17(1):502-508. doi: 10.3892/mmr.2017.7868. Epub 2017 Oct 
      25.